Sterile dry powder filling of cefepime hydrochloride for 0.5 g, 1 g, and 2 g IM/IV vials is governed less by API potency than by powder flow, electrostatic charge, and residual moisture transfer inside an isolator or restricted-access barrier system. The crystalline powder is typically blended with L-arginine at approximately 725 mg per 1 g of cefepime activity to control reconstitution pH between 4.0 and 6.0; the fill weight is calculated from the as-is assay and water content rather than from the nominal label claim alone. Aseptic filling lines operating in an ISO 5 environment under EU GMP Annex 1 require continuous viable particle monitoring, while relative humidity is maintained between 20% and 30% to limit caking on dosator pins and vacuum drum surfaces. Karl Fischer titration according to USP 921 is used to confirm that residual water remains below the compendial limit and, in many batch records, below 1.5% w/w to reduce hydrolytic degradation of the β-lactam ring during shelf life. Laser diffraction particle sizing by ISO 13320:2020 and sieve analysis are applied to keep the D90 below 250 µm because larger agglomerates slow reconstitution with sterile water for injection, while an excess of fines below 10 µm increases electrostatic deposition on glass vial walls and elastomer closures. In-process fill weight checks are performed gravimetrically at intervals not exceeding 15 min, and the final container is sampled for visible particulate matter according to USP 790.

What Are the Critical Hold-Time Limits for Cefepime Hydrochloride in Sterile Bulk Solution?

Handling cefepime hydrochloride as a sterile bulk solution before aseptic filling shifts the process risk from powder flow to β-lactam hydrolysis, bioburden accumulation, and filter compatibility. Bulk dissolution is performed in a jacketed 316L stainless steel vessel at 10°C to 15°C using Water for Injection; the solution concentration is typically 50 mg/mL to 100 mg/mL of cefepime activity, with L-arginine added to maintain a pH of 4.0 to 6.0. Prefiltration bioburden is monitored according to EU GMP Annex 1 and is held at not more than 10 CFU/100 mL before the solution is passed through a 0.22 µm rated PVDF or PES membrane validated under ASTM F838-20. Sterile filtration is followed by a hold-time validation that records clarity, pH, assay, related substances, and endotoxin levels at defined time points; manufacturer stability data for cefepime reconstituted in 0.9% sodium chloride injection or 5% dextrose injection support 24 h at 20°C to 25°C, and 7 days under refrigeration at 2°C to 8°C. Prolonged exposure to dextrose-containing vehicles beyond the validated hold time increases the concentration of hydrolytic degradation products because the β-lactam ring is susceptible to acid-catalyzed cleavage; the solution should not be frozen, and any visible precipitate after filtration signals pH excursion or salt incompatibility. Endotoxin testing by USP 85 is performed on the bulk solution after filtration, with a release limit not more than 0.04 EU/mg for parenteral cefepime hydrochloride.

When Cefepime Hydrochloride Is Compounded by Automated Intravenous Admixture Devices

Automated intravenous admixture systems receive sterile cefepime hydrochloride in dry powder vials and reconstitute, dilute, and label patient-specific doses inside an ISO 5 compounding zone. The devices typically use peristaltic pumps with single-use tubing sets and gravimetric verification to prepare final concentrations of 20 mg/mL to 40 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection; the compounded product is then capped and held under controlled temperature until administration. USP 797 governs beyond-use dating for compounded sterile preparations, and cefepime manufacturer data support a 24 h room-temperature window or 7 days refrigerated if the bag or syringe remains intact and protected from light. Automated compounding requires the powder to reconstitute rapidly and completely; residual foam and undissolved particles can interfere with optical sensors and in-line 0.22 µm filtration, which is why powder-fill particle size distribution and L-arginine blending are monitored earlier in the supply chain. Gravimetric accuracy, barcode verification, and final visible inspection against USP 790 are recorded for each dose, and any deviation in pH outside 4.0 to 6.0 triggers rejection because it indicates dilution error or contamination with an incompatible drug.

Because cefepime hydrochloride is a zwitterionic cephalosporin with negligible jejunal permeability, oral tablet development rarely progresses beyond pilot-scale permeability screening and stability-box studies. Published data for oral cefepime hydrochloride tablets are limited, and no reference-listed oral product exists in major pharmacopeias; therefore, any direct compression work is treated as experimental and must not be presented as a systemic therapeutic equivalence case. When tablet prototypes are prepared, the API is screened at 40 mesh to 60 mesh, blended with microcrystalline cellulose, dibasic calcium phosphate anhydrous, and 0.5% w/w magnesium stearate, and compressed on a rotary press with a target hardness of 60 N to 80 N. Friability testing according to USP 1216 is applied to keep weight loss below 1.0%, and disintegration testing according to USP 701 is used to establish whether a film coating delays matrix hydration. The acidic environment of simulated gastric fluid without enzyme produces rapid β-lactam hydrolysis; for this reason, formulation work involving cefepime hydrochloride in oral solids is confined to short-duration dissolution media screening at pH 4.0 and pH 6.8, with no inference of oral bioavailability. Equipment contact surfaces should be stainless steel or glass-lined because the hydrochloride salt is corrosive in humid conditions and tends to adhere to aluminium tooling.

Capsule Filling, Granule Densification, and Acidic Hydrolysis in Oral Prototypes

Capsule and granule processing of cefepime hydrochloride is evaluated in development only where the objective is characterization of chemical stability under oral formulation conditions rather than production of an approved oral dosage form. Granulation is conducted by dry binding because aqueous wet massing accelerates β-lactam hydrolysis; a roller compactor with a compaction force of 30 kN to 50 kN is used to produce granules with a D50 between 200 µm and 400 µm, followed by milling through a 1.0 mm screen. The granules are filled into hard gelatin or HPMC capsules using a dosator or tamping-pin machine, and fill weight uniformity is assessed according to USP 905. Dissolution testing in 900 mL of pH 4.0 acetate buffer and pH 6.8 phosphate buffer at 37°C with paddle speed 50 rpm is used solely to track API release from the prototype matrix; the results do not establish in vivo absorption because cefepime lacks clinically meaningful oral bioavailability. Moisture pick-up during capsule banding and packaging is controlled below 2.0% w/w by Karl Fischer, and storage studies are run at 25°C/60% RH and 40°C/75% RH according to ICH Q1A(R2) only to generate degradation profiles for the experimental oral forms.

Co-Filling with Tazobactam Sodium Demands Separate Compatibility Screening

Fixed-dose injectable combinations of cefepime hydrochloride and tazobactam sodium are registered in selected markets, but their fill-line behavior cannot be extrapolated from single-API cefepime dry powder data. Tazobactam sodium contributes hygroscopicity and pH buffering capacity; therefore, a dry-blend process must be mapped for segregation risk, electrostatic interaction, and local moisture hotspots before commercial filling. Fill weight calculations use each component's as-is assay and water content according to the approved ratio, and blend uniformity is evaluated with near-infrared spectroscopy or HPLC to keep relative standard deviation below 5.0% in 10 sampling points. Reconstitution compatibility is tested in water for injection, 0.9% sodium chloride, and 5% dextrose at 25°C and 2°C to 8°C; published data for this specific configuration are limited, and batch-specific compatibility is required because tazobactam sodium can alter the final pH and degradation kinetics of the β-lactam. Any visible precipitate or pH outside 4.0 to 6.0 after reconstitution invalidates the dry blend.

For powder-filled and lyophilized cefepime HCl vials, container closure integrity testing is a release and stability commitment, not a routine visual check. Elastomeric stoppers compounded with chlorobutyl or bromobutyl polymer are subjected to dye ingress, vacuum decay, or helium leak methods validated against a known positive control incorporating a 5 µm glass capillary defect; the detection limit is stated in the validation protocol and is reviewed against USP 1207. Extractables screening is performed under conditions that simulate the reconstitution solvent, typically water for injection at 25°C for 24 h, and the resulting chromatographic profile is compared with the stopper manufacturer's master formula to rule out leachable accelerators such as 2-mercaptobenzothiazole. The vial is depyrogenated at 250°C for not less than 30 min in a validated hot-air tunnel, while the elastomer closures are steam-sterilized at 121°C for 15 min and dried to a moisture endpoint. Headspace residual oxygen is not routinely controlled for dry powder vials because the β-lactam is more sensitive to moisture than to oxygen, but nitrogen flushing is applied when the line is located in a high-humidity coastal site. Final product is sampled for subvisible particulate matter according to USP 788, and the compendial acceptance limits shown in Table 1 distinguish small-volume and large-volume parenteral configurations.